# A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-02)

> **NCT00520390** · PHASE1 · COMPLETED · sponsor: **Enzon Pharmaceuticals, Inc.** · enrollment: 34 (—)

## Conditions studied

- Lymphoma
- Advanced Solid Tumors

## Interventions

- **DRUG:** EZN-2208

## Key facts

- **NCT ID:** NCT00520390
- **Lead sponsor:** Enzon Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 34 (—)
- **Last updated:** 2010-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00520390

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00520390, "A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-02)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00520390. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*